Tranexamic acid implementation for postpartum haemorrhage in Australian hospitals

Postpartum haemorrhage remains one of the most time-critical emergencies in maternity care. Blood loss can accelerate within minutes after birth, and the clinical picture may be difficult to judge while a team is managing uterine atony, retained placenta, genital tract trauma, coagulopathy or an operative complication. Tranexamic acid (TXA), an antifibrinolytic medicine, has become an important part of early treatment because it helps preserve formed clots when given promptly.

The discussion belongs within the wider perinatal medicine community represented by the FAOPS 2020 congress site, which brought Asian and Oceania clinicians together around obstetric and neonatal research before the Tokyo meeting was cancelled during the COVID-19 pandemic. For Australian hospitals, the practical issue is now implementation: ensuring that the right woman receives the right dose quickly, alongside uterotonics, blood products, source control and senior clinical support.

Why early treatment matters

The strongest evidence for therapeutic TXA comes from the WOMAN trial, which included women with clinically diagnosed postpartum haemorrhage after vaginal or caesarean birth. A 1 g intravenous dose administered as soon as possible, preferably within three hours of birth, reduced death from bleeding. If haemorrhage continued after 30 minutes or restarted within 24 hours, a second 1 g dose could be given. The benefit was greatest when treatment was not delayed.

TXA does not replace uterine massage, oxytocin, examination, repair of lacerations, removal of retained tissue or escalation to surgery. It is one component of a coordinated major obstetric haemorrhage response. A useful local protocol therefore places TXA beside the first-line actions rather than in a separate medication pathway that someone must remember later.

The practical trigger should be based on ongoing bleeding and clinical concern, not on a perfect estimate of blood loss. Weighing swabs, measuring suction canisters and recording cumulative loss are valuable, yet visual estimation alone can substantially underestimate haemorrhage. Tachycardia, hypotension, pallor, altered mental state and poor urine output should prompt urgent reassessment even when the recorded volume appears modest.

Turning evidence into a usable protocol

An Australian maternity unit should specify who may prescribe and administer TXA, where it is stored, how it is labelled and what documentation is required. In many hospitals, a pre-positioned emergency pack in the birth suite, operating theatre and obstetric emergency area is more reliable than relying on a central pharmacy supply. The pack can contain the medicine, compatible equipment, a dosing card and a checklist that links TXA with blood collection and escalation.

The usual treatment regimen is 1 g IV, commonly infused over about 10 minutes, with a second 1 g dose for ongoing or recurrent bleeding according to local policy. Staff should check allergies, renal impairment, previous thromboembolic disease and other contraindications or precautions in the relevant product information and hospital guideline. A protocol must also clarify whether the dose has already been administered by ambulance, a retrieval team or another clinical area.

Implementation works best when the medication order is embedded in a major haemorrhage pathway. The first response can assign separate roles for airway and circulation, medication, blood bank communication, documentation, family liaison and source control. This prevents the midwife or junior doctor coordinating the room from having to leave the patient to locate TXA. The same approach is useful in a busy metropolitan service in Melbourne or Brisbane and in a smaller regional hospital where staff may cover several roles at once.

Training across different maternity settings

A medication policy has little value if clinicians are uncertain about the threshold for action. Short, repeated simulation sessions can rehearse recognition of primary PPH, calling for help, administering TXA, activating a massive transfusion protocol and arranging transfer. Scenarios should include vaginal birth, caesarean birth, concealed bleeding, placenta accreta spectrum and haemorrhage in a woman who initially appears stable.

Education should be multidisciplinary. Midwives, obstetricians, anaesthetists, theatre nurses, emergency clinicians, pharmacists, pathology staff and retrieval teams all influence the time to treatment. Regional and rural services may need additional planning for limited on-site blood stocks, after-hours pharmacy access and transfer by road or air. A woman in Dubbo, Cairns or a remote Northern Territory community may face a very different pathway from someone in a tertiary centre near Royal Prince Alfred or Monash Medical Centre.

Professional learning can be refreshed through broader clinical education as well as local drills; for example, CME learning opportunities illustrate how specialty organisations present continuing education resources. The key Australian requirement is that any external material be translated into a hospital-approved workflow, with credentialing, supervision and documentation responsibilities made clear.

Building a response around the whole patient

PPH management must continue beyond the initial injection. Clinicians need to identify the cause using the familiar framework of tone, trauma, tissue and thrombin. Uterine atony may respond to uterotonics and uterine compression, while a cervical tear requires repair and retained placenta may require manual removal or theatre management. If bleeding continues, TXA cannot compensate for delayed source control.

The response should also account for anaemia, shock, pain, breastfeeding, informed consent and psychological safety. A woman may remember fragmented conversations, a crowded room and fear for her life long after the haemorrhage has resolved. Clear explanations, an interpreter where needed, respectful involvement of a support person and a structured debrief can improve recovery. Follow-up should address haemoglobin, iron replacement, fatigue, mood and the woman’s questions about future pregnancy.

Communication materials should be plain, culturally safe and available in formats suited to the local population. A hospital website may include links to practical health information, such as this composite bonding guide, but postnatal haemorrhage information should remain clearly separated from elective dental content so families are not distracted from urgent advice. Digital resources should state when to seek emergency care, who to contact and what symptoms require immediate review.

Neonatal and maternal teams also need to communicate after a complicated birth. A newborn may require assessment or treatment for an unrelated emergency, and the parent may be recovering from substantial blood loss at the same time. Cross-team familiarity with neonatal drainage guidance reflects the value of coordinated perinatal education, where maternity and neonatal clinicians understand each other’s priorities without confusing separate clinical indications.

Measuring whether implementation is working

Hospitals should audit the interval from recognition of PPH to TXA administration, the proportion of eligible women receiving it within three hours of birth, repeat dosing when indicated, adverse events and clinical outcomes. The audit should distinguish vaginal and caesarean births and examine whether delays occurred in decision-making, prescribing, drug retrieval, IV access or administration.

Data are most useful when combined with case review. A woman may have received TXA within six minutes yet experienced a poor outcome because placenta accreta was recognised late. Another may have had a modest recorded blood loss but required urgent treatment because shock developed quickly. Reviewing these cases helps teams improve escalation criteria rather than judging performance by a single number.

Governance should include pharmacy, transfusion services, maternity leadership, Aboriginal and Torres Strait Islander health representatives, quality teams and consumer voices. Australia’s geography and health-system variation make a single national workflow difficult to apply identically everywhere. Local protocols should align with state or territory guidance, national obstetric recommendations and the capabilities of each facility, including referral arrangements.

Prevention and antenatal planning remain part of the same safety system. Risk factors such as placenta praevia, previous PPH, anaemia, multiple pregnancy and bleeding disorders should be documented before labour. Education on GBS screening updates is a separate perinatal issue, yet it demonstrates why maternity teams benefit from maintaining current, clearly organised clinical guidance across pregnancy, birth and the newborn period.

Making TXA routine in a PPH response is a practical patient-safety project. Australian services can begin by checking stock locations, confirming the dose pathway, running a short simulation and auditing the next cases. Review the results with the people who provide care and the families who experience it, then keep the protocol visible, rehearsed and ready for the next birth.